Compare NetEase Inc (NTES) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NetEase Inc trades at $124.4 (market cap $82.75B), while State Street SPDR S&P Biotech ETF trades at $159.2. The key difference: NetEase Inc pays a 2.36% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NetEase Inc nearer its low. Which is the better fit depends on your goals.
| NTES | XBI | |
|---|---|---|
Market Cap | $82.75B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $159.34 | $164.28 |
52-Week Low | $109.26 | $86.92 |
Enterprise Value | $59.05B | — |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $124.26, down 6.86% over 24 hours, with a P/E of 16.31 and P/S of 4.86. Recent earnings show a beat in Q1 2026 but misses in prior quarters. The company maintains strong profitability with a net income margin of 29.84% and ROE of 22.12%. Technical indicators signal a bullish trend, supported by positive analyst sentiment with 82% buy ratings.
The outlook for NTES is positive due to robust fundamentals and international expansion potential. Risks include earnings volatility and competitive pressures in the gaming sector. Upside is supported by a $0.72 dividend and strong cash flow generation, though investors should monitor quarterly performance against expectations.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
